Abolon Group

Abolon Group advises “Haus auf der Hardt” on its sale to puraVita Abolon acted as the advisor to the shareholders in the sale of the “Haus auf der Hardt” reintegration facilities to puraVita GmbH. The transaction was completed in late April 2024. It was agreed not to disclose the transaction value. Headquartered in Nümbrecht, Germany, the “Haus auf der Hardt” is a specialized service provider for reintegration assistance. Coverage includes care for inpatient and outpatient individuals. The facilities include both open and closed areas as well as outpatient care for people with physical restrictions. #Haus #auf #der #Hardt #healthcare

Abolon Group advises on the sale of COAT-X, an innovator in high performance thin-film encapsulation technologies    Abolon has been the adviser to the shareholders of COAT-X, Switzerland, on its sale to the French surface functionalization and protection solutions provider Plasmalex group. The transaction has been closed on 25 April 2024. It was agreed not to disclose the purchase price.   COAT-X is a leading solutions provider for high performance thin-film encapsulation technologies. The offering includes a broad range of parylene, ultra-tight multilayer and ALD barrier contract coating solutions and equipment to various industries ranging from medical technology over electronics to micromechanics. #encapsulation #technologies #switzerland #coatx #plasmalex

Abolon Group was the exclusive advisor to the shareholders of This AG / Sophi on its sale to Rayner, a global leader in products for cataract surgery, headquartered in the UK. The acquisition closed on 17th January 2024. It was agreed not to disclose the purchase price. Rayner announced that it has entered into a definitive agreement to acquire Swiss-based This AG, the inventor, developer and manufacturer of Sophi phaco emulsification machines. Sophi - Swiss Ophthalmology Innovation is an innovative phaco technology providing mobility, simplicity, and safety within the operating theatre. With advanced features including triple pump fluidics, active IOP control, clean venturi and day cassette, cable free power supply and wireless communication, Sophi presents a truly advanced surgical system. The acquisition will enhance Rayner’s breadth of high-quality products for cataract surgery, enabling provision of a full offering also encompassing IOLs, OVDs, eye drops, pharmaceuticals, digital tools, and single-use recyclable instruments. #cataract #phaco #emulsification #machines #this #sophi #rayner

Abolon Group is the exclusive adviser to Medipart AG, Switzerland, ("Medipart") which has signed a share purchase agreement on 30th August 2019 to sell its stake of 73.4% in the share capital of HumanOptics Holding AG ("HumanOptics" or the "Company") to a Chinese investor. The closing of the sale is subject to customary closing conditions, including approval by the Chinese public authorities. HumanOptics is a listed stock corporation with registered office in Erlangen, Germany. The Company is active in the development, manufacturing and distribution of implantable premium intraocular solutions. The Company's shares are listed in the open market of the Frankfurt Stock Exchange. Its market capitalisation was € 56.5 million as of 29 August 2019, pre announcement of the transaction. Abolon AG is a healthcare-focused advisory firm with a long track-record in medical devices transactions. This transaction follows a series of transactions involving publicly listed entities including Sigvaris' acquisition of compression stockings business Pani Teresa Medical (Warsaw stock exchange)) and WaveLight's (German stock exchange) sale of its urology laser unit.

Ardian has acquired Riemser Arzneimittel In September 2012, Ardian (previously known as Axa Private Equity) completed the acquisition of Riemser Pharma, the specialty pharma business from the owners and funds managed by TVM Capital Healthcare and GE Capital. Abolon’s M&A team had been mandated by Ardian alongside Abolon’s commercial DD team on this transaction. Riemser Arzneimittel generated annual revenues of EUR 100m in 2011 and has 500 employees. With this transaction, Ardian will be supporting Riemser’s strategy of continued specialization and internationalization.

Abolon advises VITAL Zahnärzte on its sale to a leading dentistry group Abolon Group was the exclusive advisor to the shareholders of VITAL Zahnärzte dentistry group on its sale to one of the 3 largest European oral care organizations. The transaction was completed in early October 2022. It was agreed not to disclose the transaction value. VITAL Zahnärzte consist of 3 dental clinics in Southern Germany, leading Southern Germany in size. The group offers the full range of dentistry services with a focus on high-quality treatment, fully digitalized processes, local lab support in each practice and patient-friendly opening hours.

Abolon Group advises L&W Intensivpflege on its sale to Linimed Abolon was the exclusive advisor to the shareholders on the sale of L&W Intensivpflege GmbH to Linimed, one of the leading German providers in the field of outpatient intensive care. The transaction was completed at the end of February 2022. It was agreed not to disclose the transaction value. L&W Intensivpflege (consisting of Advivo – ambulante Beatmung GmbH, L&W Intensivpflegedienst GmbH und L&W Intensivpflege GmbH) is a specialized care service for intensive care and home ventilation in out-patient living groups (`Wohngruppen`) and 24-hour care at home in the greater Munich area and Lower Bavaria.

Abolon advises Halder on the acquisition of an acute care hospital in Germany Abolon has introduced halder, a leading German investment company into DACH mid-size companies, to the Helios Klinik Volkach situation and acted as an adviser on this acquisition through an investment vehicle founded by Halder. Alongside the hospital, previously the district hospital, two partner policlinics (‘MVZs’) have been part of the transaction. The transaction has been signed in early September 2021. The transaction value has been agreed to be kept confidential. Klinik Volkach is a SGB V, §108, clinic listed in the state hospital plan (‘Landesbettenplan’). The hospital has increasingly focused on orthopaedic surgery.

Abolon advises Renaissance on its investment in Baitella AG The Renaissance Foundation & Management has become a majority shareholder in Baitella AG | FISSO. Together with the management, Renaissance will develop the globally successful quality products for medical applications under the “Fisso” brand. Baitella AG was founded by Carlo Baitella in 1978 and, with its Fisso products, is the world's leading supplier of high-quality articulated tripods. The company supplies both the medical and industrial segments with articulated tripods and accessories in standard and customer versions. Abolon Group has advised Renaissance investment with a team of specialist advisors on this transaction.

Abolon advises Medipart on the sale of a majority stake in Actiol GmbH, an innovator in ophthalmic biomaterials Abolon has been the exclusive adviser to Medipart AG, Switzerland, ("Medipart") on the sale of its majority stake in the share capital of Actiol GmbH ("Actiol" or the "Company") to an international investor group. The transaction has been closed end of June 2021. The transaction value has been agreed to be kept confidential. Actiol is a stock corporation with registered office in Amöneburg, Germany. The Company is active in development and manufacturing of ophthalmic biomaterials, particularly acrylic IOL polymers.